RxDoctor Payments Data

Aiman Hassan, MD

Internal Medicine · Fort Wayne, INNPI 1588683122

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 20 payments — averaging $66.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$300
  • AstraZeneca$281
  • Phathom Pharmaceuticals, Inc.$250
  • Pfizer$122
  • Axsome Therapeutics, Inc.$120
  • Biohaven Pharmaceutical Holding Company Ltd.$118
  • plus $148 from 2 others

What the payments were for

  • Food & beverage$1,338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$23,707
Medicare patients
45
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban22$28,227
EliquisApixaban12$8,196
Combivent RespimatIpratropium/Albuterol Sulfate13$7,145
TrintellixVortioxetine Hydrobromide11$5,583
Albuterol Sulfate HfaAlbuterol Sulfate71$1,641
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,089
Gabapentin59$975
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$608
Atorvastatin Calcium91$601
Levothyroxine Sodium44$483
Amlodipine Besylate66$429
Potassium Chloride35$398
Cephalexin14$345
Omeprazole32$318
Tramadol Hcl51$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$8,19612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →